Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966194 · ClinicalTrials.gov registry record · Phase 2
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
A Phase 2 study of Oral Mucositis, sponsored by EpicentRx.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
- 14
- Study locations
NCT05966194 is a Phase 2 study of Oral Mucositis that is actively recruiting participants, run by EpicentRx. The registered enrollment target is 216 participants, above the 86-participant average among 10 other Oral Mucositis trials with a reported enrollment target (151% higher). The trial reports 14 study locations across 13 states.
The verdict
NCT05966194, a Phase 2 study of Oral Mucositis, is actively recruiting participants, sponsored by EpicentRx.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.
Conditions Studied
Interventions
- RADIATION Intensity Modulated Radiation Therapy (IMRT)
- DRUG RRx-001
- DRUG Cisplatin for injection 100 mg/m2
Study Locations (14)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- The University of Arizona Cancer Center - Tucson
Florida
- Miami Cancer Institute - Miami
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Indiana
- Parkview Cancer Institute - Fort Wayne
Louisiana
- Willis Knighton Cancer Center - Shreveport
Maryland
- Sandra and Malcolm Berman Cancer Institute - Baltimore
Michigan
- University of Michigan - Ann Arbor
Nevada
- Renown Regional Medical Center - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966194
The ClinicalTrials.gov registry entry for NCT05966194 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 86-participant average among 10 other Oral Mucositis trials with a reported enrollment target (151% higher). The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oral Mucositis appearing as the primary indexed condition, and to 3 interventions - of which Intensity Modulated Radiation Therapy (IMRT) is the first listed.
NCT05966194 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05966194 about?
NCT05966194 is a clinical study titled "RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer". The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with th...
What is the current status of trial NCT05966194?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2024-04-02. Estimated completion is 2025-10-01.
What conditions does trial NCT05966194 study?
This clinical trial studies the following conditions: Oral Mucositis.
What interventions are being tested in trial NCT05966194?
The interventions under investigation include: Intensity Modulated Radiation Therapy (IMRT) (RADIATION), RRx-001 (DRUG), Cisplatin for injection 100 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT05966194?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966194 being conducted?
This trial has 14 study locations across Arizona, Florida, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy
RECRUITING · Phase 2
-
Photobiomodulation for the Prevention of Oral Mucositis
ACTIVE NOT RECRUITING · Phase 2
-
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
ACTIVE NOT RECRUITING · Phase 2
-
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
COMPLETED · Phase 2
-
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
COMPLETED · Phase 2
-
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.